Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

PHVS

Pharvaris NV

May 22 • 04:00PM ET

29.68

-0.86 -2.82 %

Healthcare • Biotechnology • Netherlands • Small • NASD

Peers: BCRX KALV IONS CRSP NTLA

| Held by: IBB IEFA SCZ SBIO EWN ONEQ GWX BBC IBBQ IEUS

Index	-	P/E	-	EPS (ttm)	-3.18	Insider Own	57.74%	Shs Outstand	65.42M	Perf Week	-2.37%
Market Cap	1.94B	Forward P/E	-	EPS next Y	-2.78	Insider Trans	-0.55%	Shs Float	27.71M	Perf Month	8.76%
Enterprise Value	1.66B	PEG	-	EPS next Q	-0.79	Inst Own	42.72%	Short Float	3.79%	Perf Quarter	7.30%
Income	-195.21M	P/S	-	EPS this Y	9.79%	Inst Trans	-0.48%	Short Ratio	4.07	Perf Half Y	20.95%
Sales	0.00M	P/B	7.13	EPS next Y	10.97%	ROA	-68.82%	Short Interest	1.05M	Perf YTD	6.95%
Book/sh	4.16	P/C	6.82	EPS next 5Y	30.18%	ROE	-75.71%	52W High	33.33 -10.95%	Perf Year	81.09%
Cash/sh	4.35	P/FCF	-	EPS past 3/5Y	-11.96% -21.68%	ROIC	-71.53%	52W Low	15.46 91.98%	Perf 3Y	249.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.64% 5.57%	Perf 5Y	46.21%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.22%	Oper. Margin	-	ATR (14)	1.58	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.24	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	50.52	Recom	1.14
Dividend Gr. 3/5Y	- -	Current Ratio	11.24	EPS Q/Q	21.54%	SMA20	-1.03%	Beta	-2.35	Target Price	46.41
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	3.96%	Rel Volume	1.13	Prev Close	30.54
Employees	129	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	15.68%	Avg Volume	258.61K	Price	29.68
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.03% -	Trades		Volume	291,071	Change	-2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-26	Initiated	Wolfe Research	Outperform	$42
Mar-09-26	Initiated	RBC Capital Mkts	Outperform	$52
Oct-15-25	Initiated	H.C. Wainwright	Buy	$60
Oct-09-25	Upgrade	BofA Securities	Underperform → Neutral	$27
Jun-11-25	Initiated	Guggenheim	Buy	$32
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$28
Sep-25-23	Initiated	Wedbush	Outperform	$27
Aug-15-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$10 → $34
Oct-05-22	Initiated	Bryan Garnier	Buy	$16
Sep-13-22	Resumed	JMP Securities	Mkt Outperform	$34 → $18
Aug-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$40 → $10
Aug-22-22	Downgrade	BofA Securities	Neutral → Underperform	$26 → $13
May-25-22	Initiated	JMP Securities	Mkt Outperform	$34
Mar-02-21	Initiated	SVB Leerink	Outperform	$50
Mar-02-21	Initiated	Oppenheimer	Outperform	$48
Mar-02-21	Initiated	Morgan Stanley	Overweight	$51
Mar-02-21	Initiated	BofA Securities	Neutral	$41

Show Previous Ratings

May-12-26 04:05PM	Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +5.41%
May-11-26 04:15PM	Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-08-26 06:00AM	Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares (GlobeNewswire)
Apr-20-26 06:50AM	Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference (GlobeNewswire)
Apr-09-26 09:40AM	Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls (The Fly)
06:50AM	Loading…
Apr-02-26 06:50AM	Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Apr-01-26 08:00PM	Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect? (Quartz)
Mar-20-26 06:50AM	Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology (GlobeNewswire)
Mar-11-26 06:50AM	Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology (GlobeNewswire) +5.95%
Mar-02-26 06:50AM	Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026 (GlobeNewswire)
Feb-10-26 06:50AM	Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting (GlobeNewswire)
Jan-12-26 06:50AM	Pharvaris Outlines 2026 Strategic Priorities (GlobeNewswire)
Dec-21-25 09:57AM	What Does Wall Street Think About Pharvaris N.V. (PHVS)? (Insider Monkey)
Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks) -5.70%
Dec-03-25 04:15PM	Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment (Investor's Business Daily) +21.75%
06:50AM	Loading…
06:50AM	Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks (GlobeNewswire)
Nov-12-25 06:50AM	Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.01%
Nov-10-25 06:50AM	Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting (GlobeNewswire)
Oct-23-25 06:50AM	Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting (GlobeNewswire)
Aug-12-25 04:05PM	Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-24-25 04:05PM	Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-22-25 09:22PM	Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants (GlobeNewswire) -9.86%
04:05PM	Pharvaris Announces Proposed Public Offering of Ordinary Shares (GlobeNewswire)
Jul-10-25 06:50AM	Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 (GlobeNewswire) +7.19%
Jun-27-25 06:50AM	Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit (GlobeNewswire) -5.03%
Jun-16-25 06:50AM	Pharvaris Presents Data Highlighting the Potential for Deucrictibant to Prevent and Treat Bradykinin-Mediated Angioedema Attacks at the EAACI Congress (GlobeNewswire)
Jun-10-25 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-02-25 06:50AM	Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema (GlobeNewswire)
May-19-25 06:50AM	Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses (GlobeNewswire)
May-13-25 04:05PM	Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:50AM	Loading…
May-12-25 06:50AM	Pharvaris to Host a Virtual R&D Call "Deucrictibant: Beyond HAE Type 1/2" on June 4 (GlobeNewswire)
Apr-07-25 06:58AM	Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.49%
Apr-02-25 06:30AM	EC grants orphan designation for Pharvaris' deucrictibant drug (Pharmaceutical Business Review)
Apr-01-25 06:50AM	Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission (GlobeNewswire) -5.54%
Mar-03-25 06:50AM	Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress (GlobeNewswire)
06:48AM	Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire)
Jan-31-25 02:01PM	Why Pharvaris (PHVS) Is Advancing Today (Insider Monkey)
Jan-23-25 02:07AM	Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? (Insider Monkey)
Jan-13-25 06:50AM	Pharvaris Outlines 2025 Strategic Priorities (GlobeNewswire) -7.81%
Dec-06-24 06:47AM	Pharvaris price target lowered to $46 from $50 at JMP Securities (TipRanks)
Nov-13-24 04:10PM	Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Nov-12-24 06:50AM	Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire) -6.64%
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-24-24 08:00AM	Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting (GlobeNewswire)
Oct-16-24 06:50AM	Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings (GlobeNewswire)
Oct-15-24 06:50AM	Pharvaris to Host Virtual Investor Event on October 23, 2024 (GlobeNewswire)
Oct-03-24 06:50AM	Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop (GlobeNewswire)
Sep-05-24 06:50AM	Pharvaris Provides Business Update and Expands Development Program for Deucrictibant (GlobeNewswire) +10.34%
06:49AM	Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024 (GlobeNewswire)
06:48AM	Pharvaris Presents Data at the Bradykinin Symposium 2024 (GlobeNewswire)
Aug-28-24 06:50AM	Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium (GlobeNewswire)
Aug-14-24 06:50AM	Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.55%
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
Jun-11-24 06:50AM	Pharvaris Announces Annual Meeting of Shareholders (GlobeNewswire)
Jun-04-24 06:50AM	Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses (GlobeNewswire) -5.31%
May-13-24 06:50AM	Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses (GlobeNewswire)
May-08-24 11:55PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024 (InvestorPlace) -7.82%
04:10PM	Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-10-24 09:52PM	PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
04:08PM	Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer (GlobeNewswire)
Apr-04-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference (GlobeNewswire)
Mar-18-24 06:50AM	Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses (GlobeNewswire) +6.34%
Mar-06-24 06:50AM	Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses (GlobeNewswire) +5.86%
Mar-05-24 06:50AM	Pharvaris to Participate in the Leerink Global Biopharma Conference 2024 (GlobeNewswire)
Feb-22-24 06:50AM	Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting (GlobeNewswire)
Feb-16-24 06:50AM	Pharvaris Announces Extraordinary Meeting of Shareholders (GlobeNewswire)
Jan-26-24 06:50AM	Pharvaris to Present at the WSAAI Annual Meeting 2024 (GlobeNewswire)
Jan-23-24 09:34AM	Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program (Zacks)
Jan-22-24 04:07PM	Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision (Investor's Business Daily) +6.27%
07:34AM	FDA lifts remaining hold on Pharvaris' HAE drug, clearing path to phase 3 (FierceBiotech.com)
06:50AM	Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Jan-05-24 06:50AM	Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities (GlobeNewswire)
Dec-08-23 06:00PM	Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Dec-07-23 03:17PM	Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal (Zacks)
Dec-06-23 10:16AM	Why Is Pharvaris (PHVS) Stock Up 36% Today? (InvestorPlace) +18.14%
09:33AM	Pharvaris' oral hereditary angioedema med slashes attacks in turnaround post-FDA hold (FierceBiotech.com)
07:02AM	Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants (GlobeNewswire)
06:56AM	Pharvaris shares spike as drug appears to prevent symptoms of rare disorder (BioPharma Dive)
06:50AM	Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks (GlobeNewswire)
Nov-30-23 06:50AM	Pharvaris to Present at the GA LEN UCARE Conference 2023 (GlobeNewswire)
Nov-15-23 06:50AM	Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer (GlobeNewswire) -11.49%
Nov-09-23 11:00AM	Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Nov-02-23 06:50AM	Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 06:50AM	Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting (GlobeNewswire)
Oct-13-23 06:50AM	Pharvaris To Present at the APAAACI 2023 International Conference (GlobeNewswire)
Oct-04-23 07:34AM	Pharvaris To Present at the CIIC Fall 2023 Conference (GlobeNewswire)
Sep-19-23 06:50AM	Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference (GlobeNewswire) +16.68%
Sep-06-23 06:51AM	Pharvaris To Present at the 18th German Allergy Congress (GlobeNewswire)
06:50AM	Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-31-23 08:09PM	Expect at Least 60% Upside, Says Morgan Stanley About These 2 Buy-Rated Stocks (TipRanks)
Aug-23-23 06:50AM	Pharvaris To Present at the 2023 HAEi Regional Conference EMEA (GlobeNewswire)
Aug-15-23 09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly) +8.58%
Aug-07-23 06:50AM	Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -6.91%
Jul-21-23 10:20AM	Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit (GlobeNewswire)
Jul-03-23 08:16AM	Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms with 50% ownership, institutions own 18% (Simply Wall St.)
Jun-27-23 12:11PM	Why Shares of Pharvaris N.V. Are Up Tuesday (Motley Fool) +7.96%
Jun-26-23 02:27PM	FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE (Benzinga) +27.76%
06:50AM	Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE (GlobeNewswire)

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

M.B.A.Mr. Berndt Axel Edvard Modig CPA

CFOMr. David W. Nassif J.D.

R.A.Ms. Anna Nijdam M.Sc.

Chief Technology Operations OfficerDr. Stefan Abele Ph.D.

Chief Human Resources OfficerMs. Annick Deschoolmeester

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ANNA NIJDAM	Officer	May 22 '26	Proposed Sale	30.74	5,501	169,084		May 22 05:03 PM
Bjork Elisabeth	Director	May 20 '26	Option Exercise	8.05	10,000	80,500	25,167	May 22 02:54 PM
Bjork Elisabeth	Director	May 20 '26	Sale	29.32	10,000	293,166	15,167	May 22 02:54 PM
ANNA NIJDAM	Officer	May 21 '26	Proposed Sale	30.60	1,829	55,971		May 21 05:35 PM
VIVIANE V. MONGES	Director	May 21 '26	Proposed Sale	30.29	9,667	292,853		May 21 05:31 PM
DAVID NASSIF	Officer	May 21 '26	Proposed Sale	30.31	10,000	303,076		May 21 05:27 PM
Modig Berndt	Chief Executive Officer	May 18 '26	Sale	29.22	2,292	66,977	137,500	May 20 05:33 PM
ELISABETH BJORK	Director	May 20 '26	Proposed Sale	29.32	10,000	293,166		May 20 05:23 PM
Glassman Robert	Director	May 15 '26	Option Exercise	22.31	5,333	118,979	20,500	May 19 06:48 PM
Glassman Robert	Director	May 15 '26	Sale	29.82	10,000	298,245	10,500	May 19 06:48 PM
Abele Stefan Andreas	Chief Technical Ops Officer	May 15 '26	Sale	29.82	8,748	260,864	35,194	May 19 06:44 PM
Souverijns Wim	Chief Commercial Officer	May 15 '26	Sale	29.92	10,000	299,163	45,111	May 19 06:42 PM
STEFAN ABELE	Officer	May 15 '26	Proposed Sale	29.82	8,748	260,864		May 15 05:50 PM
WIM SOUVERIJNS	Officer	May 15 '26	Proposed Sale	29.92	10,000	299,163		May 15 05:44 PM
Berndt B.A,E. Modig	Director	May 15 '26	Proposed Sale	30.70	2,292	70,364		May 15 04:31 PM
ROBERT GLASSMAN	Director	May 15 '26	Proposed Sale	29.82	8,804	262,567		May 15 04:14 PM
Lu Peng	Chief Medical Officer	May 01 '26	Option Exercise	2.59	14,166	36,690	80,249	May 05 03:51 PM
Lu Peng	Chief Medical Officer	May 01 '26	Sale	30.17	14,166	427,419	66,083	May 05 03:51 PM
Schikan Johannes Gerardus Chri	Director	Apr 30 '26	Sale	30.32	29,070	881,380	355,167	May 01 07:32 PM
Schikan Johannes Gerardus Chri	Director	Apr 29 '26	Sale	30.07	3,830	115,165	384,237	May 01 07:32 PM
Lesage Anne	Chief Early Development	Apr 30 '26	Option Exercise	7.12	21,700	154,483	74,450	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 29 '26	Option Exercise	2.59	3,700	9,583	60,150	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 30 '26	Sale	30.26	21,700	656,551	56,450	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 30 '26	Sale	30.26	19,200	580,909	133,969	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 29 '26	Sale	30.08	3,700	111,280	56,450	May 01 07:30 PM
Lesage Anne	Chief Early Development	Apr 29 '26	Sale	30.06	3,700	111,229	153,169	May 01 07:30 PM
Lu Peng	Chief Medical Officer	Apr 30 '26	Option Exercise	2.59	15,000	38,850	81,083	May 01 07:09 PM
Lu Peng	Chief Medical Officer	Apr 29 '26	Option Exercise	2.59	3,733	9,668	69,816	May 01 07:09 PM
Lu Peng	Chief Medical Officer	Apr 30 '26	Sale	30.24	15,000	453,627	66,083	May 01 07:09 PM
Lu Peng	Chief Medical Officer	Apr 29 '26	Sale	30.06	3,733	112,232	62,350	May 01 07:09 PM
Schikan Johannes Gerardus Chri	Director	Apr 22 '26	Sale	30.05	7,000	210,379	388,167	Apr 24 02:09 PM
Schikan Johannes Gerardus Chri	Director	Apr 23 '26	Sale	30.03	100	3,003	388,067	Apr 24 02:09 PM
Lesage Anne	Chief Early Development	Apr 22 '26	Option Exercise	7.69	7,500	57,645	63,450	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 23 '26	Option Exercise	2.59	100	259	56,550	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 22 '26	Sale	30.05	7,500	225,362	56,450	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 22 '26	Sale	30.05	7,000	210,358	156,969	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 23 '26	Sale	30.03	100	3,003	156,869	Apr 24 12:18 PM
Lesage Anne	Chief Early Development	Apr 23 '26	Sale	30.03	100	3,003	56,450	Apr 24 12:18 PM
Lu Peng	Chief Medical Officer	Apr 22 '26	Option Exercise	2.59	7,001	18,133	73,084	Apr 24 11:27 AM
Lu Peng	Chief Medical Officer	Apr 23 '26	Option Exercise	2.59	100	259	66,183	Apr 24 11:27 AM
Lu Peng	Chief Medical Officer	Apr 22 '26	Sale	30.05	7,001	210,402	66,083	Apr 24 11:27 AM
Lu Peng	Chief Medical Officer	Apr 23 '26	Sale	30.03	100	3,003	66,083	Apr 24 11:27 AM
GrayMatters Consulting B.V.	Officer	Apr 22 '26	Proposed Sale	29.15	30,000	874,500		Apr 22 05:17 PM
PENG LU	Officer	Apr 22 '26	Proposed Sale	29.15	40,000	1,166,000		Apr 22 04:29 PM
ANNE SIMONNE J. LESAGE	Officer	Apr 22 '26	Proposed Sale	29.15	33,000	961,950		Apr 22 04:29 PM
Hans H. Schikan	Director	Apr 22 '26	Proposed Sale	29.15	40,000	1,166,000		Apr 22 04:28 PM
Modig Berndt	Chief Executive Officer	Apr 16 '26	Sale	28.60	2,292	65,559	139,792	Apr 20 03:00 PM
Berndt B.A.E. Modig	Officer	Apr 16 '26	Proposed Sale	29.14	2,292	66,789		Apr 16 04:15 PM
Modig Berndt	Chief Executive Officer	Apr 09 '26	Sale	27.74	23,333	647,281	142,084	Apr 10 01:42 PM
Berndt B.A.E. Modig	Director	Apr 08 '26	Proposed Sale	27.84	23,333	649,591		Apr 08 04:35 PM
PENG LU	Officer	Jan 02 '26	Proposed Sale	27.75	49,000	1,359,750		Jan 02 04:29 PM
ABELE STEFAN ANDREAS	Officer	Dec 04 '25	Proposed Sale	28.02	4,109	115,120		Dec 04 06:08 PM
JOHANNES GER. CHRIS. PE SCHIKA	Officer	Dec 03 '25	Proposed Sale	24.12	20,000	482,400		Dec 03 04:46 PM
Berndt B.A.E. Modig	Officer	Dec 03 '25	Proposed Sale	24.12	109,583	2,643,142		Dec 03 04:33 PM
PENG LU	Officer	Jul 14 '25	Proposed Sale	25.12	11,307	284,032		Jul 14 04:22 PM
PENG LU	Officer	Jul 11 '25	Proposed Sale	19.83	351	6,960		Jul 11 04:21 PM

Open in Screener

RCKT

Rocket Pharmaceuticals Inc

May 22 • 04:00PM ET

2.96

-0.15 -4.82 %

Healthcare • Biotechnology • USA • Small • NASD

RCKT Rocket Pharmaceuticals Inc daily Stock Chart

Peers: RGNX VYGR QURE EDIT SLDB

| Held by: VTI XBI IWM VXF IBB IWN VTWO FESM SCHA DFAS

Index	RUT	P/E	-	EPS (ttm)	-1.88	Insider Own	5.17%	Shs Outstand	109.12M	Perf Week	-8.92%
Market Cap	323.21M	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-0.96%	Shs Float	103.55M	Perf Month	-19.57%
Enterprise Value	203.59M	PEG	-	EPS next Q	1.02	Inst Own	89.46%	Short Float	20.81%	Perf Quarter	-25.81%
Income	-209.38M	P/S	-	EPS this Y	85.64%	Inst Trans	5.94%	Short Ratio	6.33	Perf Half Y	2.78%
Sales	0.00M	P/B	1.36	EPS next Y	-341.97%	ROA	-55.36%	Short Interest	21.55M	Perf YTD	-15.67%
Book/sh	2.18	P/C	2.24	EPS next 5Y	22.83%	ROE	-64.41%	52W High	6.80 -56.47%	Perf Year	-54.88%
Cash/sh	1.32	P/FCF	-	EPS past 3/5Y	14.88% 4.46%	ROIC	-80.57%	52W Low	2.19 35.16%	Perf 3Y	-86.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.39% 6.99%	Perf 5Y	-92.87%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	28.56%	Oper. Margin	-	ATR (14)	0.24	Perf 10Y	-91.82%
Dividend Ex-Date	-	Quick Ratio	6.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.25	Recom	2.43
Dividend Gr. 3/5Y	- -	Current Ratio	6.12	EPS Q/Q	23.82%	SMA20	-13.27%	Beta	0.50	Target Price	9.30
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	-20.67%	Rel Volume	0.62	Prev Close	3.11
Employees	202	LT Debt/Eq	0.09	Earnings	May 07 AMC	SMA200	-17.14%	Avg Volume	3.40M	Price	2.96
IPO	Feb 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.24% -	Trades		Volume	2,103,387	Change	-4.82%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-25	Downgrade	JP Morgan	Neutral → Underweight
Aug-20-25	Upgrade	BofA Securities	Neutral → Buy	$10
Jul-25-25	Downgrade	BofA Securities	Buy → Neutral	$4
May-30-25	Downgrade	Evercore ISI	Outperform → In-line	$5
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$7
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$8
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold	$2.50
May-28-25	Downgrade	Goldman	Neutral → Sell	$2
May-27-25	Downgrade	TD Cowen	Buy → Hold
May-27-25	Downgrade	Needham	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Dec-30-24	Initiated	Wedbush	Outperform	$32
Dec-18-24	Initiated	Jefferies	Buy	$29
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35

Show Previous Ratings

May-07-26 04:08PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (Associated Press)
04:00PM	Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress (Business Wire)
Apr-29-26 05:34AM	Rocket to sell PRV for $180m to advance gene therapy pipeline (Hospital Management)
Apr-28-26 07:00AM	Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher (Business Wire)
Mar-27-26 02:48PM	Nasdaq slides into correction amid Iran tensions and oil surge (Proactive) -19.62%
09:56AM	Loading…
09:56AM	Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI (Proactive)
07:00AM	Rocket Pharmaceuticals Announces FDA Approval of KRESLADI for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Mar-03-26 01:15PM	Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances (Proactive)
Feb-27-26 12:46PM	RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus (Zacks) +10.60%
Feb-26-26 04:04PM	Rocket Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress (Business Wire)
Feb-23-26 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire) +5.56%
Feb-18-26 07:44PM	Morgan Stanley Names Rocket Pharmaceuticals (RCKT) as Key Beneficiary of 2026 Biotech Sector Recovery (Insider Monkey) +8.41%
Jan-05-26 07:00AM	Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-15-25 11:10PM	Rocket Pharmaceuticals (RCKT) Stock Target Reduced Following Q3 2025 Update on Cash Position (Insider Monkey)
11:57AM	Loading…
Dec-09-25 11:57AM	Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions (PR Newswire)
Nov-25-25 07:00AM	Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-18-25 09:41AM	Amazon downgraded, Alphabet upgraded: Wall Street's top analyst calls (The Fly)
Nov-06-25 04:09PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Oct-26-25 06:43AM	Is Rocket Pharmaceuticals (RCKT) One of the Best NASDAQ Stocks Under $5 to Buy Now? (Insider Monkey)
Oct-15-25 11:31AM	RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy (Zacks)
Oct-14-25 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) +23.05%
Oct-10-25 04:00PM	Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.81%
Oct-03-25 11:33AM	Rocket ditches blood disorder gene therapy in ongoing pipeline pivot (Pharmaceutical Technology)
Aug-28-25 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
07:10AM	Rocket to relaunch rare disease trial after FDA approval (Clinical Trials Arena)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com) +28.87%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Loading…
07:00AM	Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease (Business Wire)
06:46AM	Rocket can resume gene therapy trial after FDA lifts hold (BioPharma Dive)
Aug-19-25 12:09AM	Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains 'Hold' Rating (Insider Monkey)
Aug-17-25 11:41PM	Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform (Insider Monkey)
Aug-07-25 04:07PM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -7.44%
04:00PM	Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Aug-06-25 04:24PM	Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 (Newsfile)
Aug-05-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-30-25 04:37PM	Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025 (Newsfile)
01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com)
Jul-29-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-24-25 07:00AM	Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -8.98%
Jul-17-25 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy (Business Wire) +16.78%
Jul-15-25 08:58AM	Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701 (Insider Monkey) -7.87%
Jul-10-25 09:55AM	Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 \| Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways (GlobeNewswire)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks) +5.71%
09:00AM	Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
07:25AM	Rocket Pharmaceuticals receives FDA clearance of RP-A701 (TipRanks)
Jun-30-25 07:00AM	Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy (Business Wire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
09:00AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
May-28-25 06:00PM	Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow (Insider Monkey) +6.44% +5.65%
01:20PM	William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback (Insider Monkey)
11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
May-27-25 08:01PM	Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death (Insider Monkey) -62.84%
11:50AM	Top Stock Movers Now: Tesla, AutoZone, Newmont, and More (Investopedia)
11:35AM	Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies (Investopedia)
10:37AM	CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers (Yahoo Finance Video)
07:00AM	Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease (Business Wire)
May-15-25 03:15PM	Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire) +11.07%
May-13-25 08:54AM	Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey) -5.50%
May-09-25 04:30PM	Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-08-25 04:01PM	Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire) +5.07%
Apr-16-25 11:59AM	Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz (TipRanks) -5.82%
Apr-10-25 11:16AM	Rocket Pharma Out Of Orbit, But Ready For Relaunch (Seeking Alpha) -8.52%
Apr-09-25 10:55AM	Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.73%
Apr-03-25 07:00AM	Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -11.75%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -12.89%
Mar-26-25 10:40AM	Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? (InsiderMonkey) -5.88%
Feb-27-25 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jan-02-25 04:00PM	Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 08:05AM	Wedbush starts Rocket Pharmaceuticals with Outperform into inflection year (TipRanks)
Dec-18-24 02:16PM	Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' (Investopedia)
Dec-11-24 07:00AM	Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
Dec-10-24 04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-26-24 07:00AM	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-18-24 11:00AM	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference (Business Wire)
Nov-12-24 04:01PM	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breaking Science Sessions (Business Wire)
Nov-08-24 07:00AM	Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-07-24 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Sep-17-24 07:00AM	Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease (Business Wire) +13.54%
Sep-10-24 07:00AM	Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors (Business Wire)
Aug-27-24 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-05-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jun-28-24 12:30PM	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment (Investopedia)
07:27AM	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) (Business Wire)
Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Gen. CounselMr. Martin Louis Wilson J.D.

Chief Operating OfficerMr. Christopher Stevens

VP of FinanceMr. John C. Militello CPA

Chief Science & Gene Therapy OfficerDr. Jonathan Schwartz M.D.

L.L.M.Ms. Meg Dodge J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shah Gaurav	CEO	May 19 '26	Sale	3.01	2,409	7,261	1,040,918	May 21 04:06 PM
Wilson Martin	General Counsel	May 19 '26	Sale	3.01	662	1,995	677,977	May 21 04:06 PM
Militello John	See Remarks	May 19 '26	Sale	3.01	384	1,157	89,780	May 21 04:06 PM
Shah Gaurav	Officer	May 21 '26	Proposed Sale	3.09	55,684	171,821		May 21 03:40 PM
Shah Gaurav	Officer	May 19 '26	Proposed Sale	3.01	2,409	7,262		May 19 03:38 PM
Militello John	Officer	May 19 '26	Proposed Sale	3.01	384	1,158		May 19 03:33 PM
Wilson Martin	Officer	May 19 '26	Proposed Sale	3.01	662	1,996		May 19 03:20 PM
Wilson Martin	General Counsel	May 13 '26	Sale	3.61	3,361	12,120	678,639	May 14 04:22 PM
Shah Gaurav	CEO	May 13 '26	Sale	3.61	2,728	9,837	1,043,327	May 14 04:19 PM
Militello John	See Remarks	May 13 '26	Sale	3.61	855	3,083	90,164	May 14 04:16 PM
Wilson Martin	Officer	May 13 '26	Proposed Sale	3.61	3,361	12,118		May 13 03:15 PM
Shah Gaurav	Officer	May 13 '26	Proposed Sale	3.61	2,728	9,836		May 13 03:13 PM
Militello John	Officer	May 13 '26	Proposed Sale	3.61	855	3,083		May 13 03:10 PM
Chaudhuri Sarbani	See Remarks	May 07 '26	Sale	3.84	17,650	67,741	267,510	May 11 07:48 PM
Chaudhuri Sarbani	Officer	May 07 '26	Proposed Sale	3.84	17,650	67,741		May 07 03:14 PM
Militello John	See Remarks	Feb 18 '26	Sale	3.34	1,157	3,862	91,019	Feb 20 04:31 PM
Shah Gaurav	CEO	Feb 18 '26	Sale	3.34	5,990	19,995	1,046,055	Feb 20 04:26 PM
Wilson Martin	General Counsel	Feb 18 '26	Sale	3.34	1,376	4,593	682,000	Feb 20 04:09 PM
Wilson Martin	General Counsel	Feb 13 '26	Sale	3.31	12,253	40,582	683,376	Feb 18 05:42 PM
Militello John	See Remarks	Feb 13 '26	Sale	3.31	3,726	12,341	92,176	Feb 18 05:38 PM
Shah Gaurav	CEO	Feb 13 '26	Sale	3.31	12,279	40,668	1,052,045	Feb 18 05:33 PM
Militello John	Officer	Feb 18 '26	Proposed Sale	3.34	1,157	3,863		Feb 18 04:58 PM
Wilson Martin	Officer	Feb 18 '26	Proposed Sale	3.34	1,376	4,594		Feb 18 04:50 PM
Shah Gaurav	Officer	Feb 18 '26	Proposed Sale	3.34	5,990	19,998		Feb 18 04:50 PM
Wilson Martin	Officer	Feb 13 '26	Proposed Sale	3.31	12,253	40,583		Feb 13 04:31 PM
Shah Gaurav	Officer	Feb 13 '26	Proposed Sale	3.31	12,279	40,669		Feb 13 03:55 PM
Schwartz Jonathan David	Officer	Feb 13 '26	Proposed Sale	3.31	14,508	48,052		Feb 13 03:53 PM
Militello John	Officer	Feb 13 '26	Proposed Sale	3.31	3,726	12,341		Feb 13 03:39 PM
Bjork Elisabeth	Director	Jan 02 '26	Buy	3.44	10,000	34,400	50,000	Jan 06 04:05 PM
Schwartz Jonathan David	See Remarks	Nov 18 '25	Sale	2.98	2,545	7,592	299,064	Nov 20 04:05 PM
Shah Gaurav	CEO	Nov 18 '25	Sale	2.98	6,276	18,721	778,296	Nov 20 04:05 PM
Militello John	See Remarks	Nov 18 '25	Sale	2.98	1,086	3,240	65,920	Nov 20 04:05 PM
Wilson Martin	General Counsel	Nov 18 '25	Sale	2.98	1,646	4,910	383,816	Nov 20 04:05 PM
Schwartz Jonathan David	Officer	Nov 18 '25	Proposed Sale	2.98	2,545	7,591		Nov 18 03:57 PM
Shah Gaurav	Officer	Nov 18 '25	Proposed Sale	2.98	6,276	18,720		Nov 18 03:26 PM
Militello John	Officer	Nov 18 '25	Proposed Sale	2.98	1,086	3,239		Nov 18 03:16 PM
Wilson Martin	Officer	Nov 18 '25	Proposed Sale	2.98	1,646	4,910		Nov 18 03:16 PM
Militello John	See Remarks	Oct 14 '25	Sale	3.96	28,918	114,581	67,006	Oct 16 04:01 PM
Militello John	Officer	Oct 14 '25	Proposed Sale	3.96	28,918	114,581		Oct 14 12:29 PM
Bjork Elisabeth	Director	Aug 27 '25	Buy	3.41	10,000	34,100	40,000	Aug 27 08:54 PM
Militello John	See Remarks	Aug 18 '25	Sale	3.06	699	2,142	56,285	Aug 20 05:00 PM
Militello John	See Remarks	Aug 19 '25	Sale	3.00	361	1,082	55,924	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 18 '25	Sale	3.06	1,680	5,149	222,414	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 19 '25	Sale	3.00	805	2,412	221,609	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 18 '25	Sale	3.06	1,004	3,077	136,050	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 19 '25	Sale	3.00	588	1,762	135,462	Aug 20 05:00 PM
Wilson Martin	Officer	Aug 19 '25	Proposed Sale	3.00	588	1,762		Aug 19 03:33 PM
Schwartz Jonathan David	Officer	Aug 19 '25	Proposed Sale	3.00	805	2,412		Aug 19 03:28 PM
Militello John	Officer	Aug 19 '25	Proposed Sale	3.00	361	1,082		Aug 19 03:28 PM
Schwartz Jonathan David	See Remarks	Aug 14 '25	Sale	3.02	11,161	33,695	224,094	Aug 18 04:35 PM
Militello John	See Remarks	Aug 14 '25	Sale	3.02	7,043	21,263	56,984	Aug 18 04:35 PM
Wilson Martin	General Counsel	Aug 14 '25	Sale	3.02	12,109	36,557	137,054	Aug 18 04:35 PM
Wilson Martin	Officer	Aug 18 '25	Proposed Sale	3.07	1,004	3,077		Aug 18 03:24 PM
Militello John	Officer	Aug 18 '25	Proposed Sale	3.07	699	2,143		Aug 18 03:10 PM
Schwartz Jonathan David	Officer	Aug 18 '25	Proposed Sale	3.07	1,680	5,150		Aug 18 03:10 PM
Militello John	Officer	Aug 14 '25	Proposed Sale	3.02	7,043	21,261		Aug 14 05:55 PM
Wilson Martin	Officer	Aug 14 '25	Proposed Sale	3.02	12,109	36,553		Aug 14 05:47 PM
Schwartz Jonathan David	Officer	Aug 14 '25	Proposed Sale	3.02	11,161	33,692		Aug 14 05:44 PM
Ondrey Aaron	Chief Financial Officer	Jul 03 '25	Sale	2.88	1,477	4,257	128,173	Jul 08 04:05 PM
Ondrey Aaron	Officer	Jul 03 '25	Proposed Sale	2.88	1,477	4,256		Jul 03 03:17 PM

PHVS

Pharvaris NV

RCKT

Rocket Pharmaceuticals Inc

Upgrade your Finviz experience